ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Unveiling the Link: Exploring Testosterone's Impact on Cardiovascular Health
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 261955" data-attributes="member: 13851"><p><strong>TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men)</strong></p><p></p><p><em>*Despite enrolment of patients with increased risk for adverse CVD events, TT was non-inferior to placebo with respect to the incidence of MACE [hazard ratio 0.96, 95% confidence interval (CI) .78–1.17] over a mean treatment duration of 22 months. <strong>However, there was an unexpected higher incidence of pulmonary embolism, atrial fibrillation, and acute kidney injury with TT. There are some important limitations of this trial. Given that normal physiologic T levels for men are 300– 1000 ng/dL, the target range of 350–750 ng/dL used in TRAVERSE may have been too low to detect certain benefits (or harms) of TT.</strong> <strong>It is generally recommended to maintain T levels in the mid-normal range (e.g. 550–750 ng/dL), which may be often accomplished with T injections as opposed to T gel. Also, given that TT is often required for long-term (e.g. lifelong) treatment, further study is clearly still needed to determine the long-term safety and efficacy of TT.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 261955, member: 13851"] [B]TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men)[/B] [I]*Despite enrolment of patients with increased risk for adverse CVD events, TT was non-inferior to placebo with respect to the incidence of MACE [hazard ratio 0.96, 95% confidence interval (CI) .78–1.17] over a mean treatment duration of 22 months. [B]However, there was an unexpected higher incidence of pulmonary embolism, atrial fibrillation, and acute kidney injury with TT. There are some important limitations of this trial. Given that normal physiologic T levels for men are 300– 1000 ng/dL, the target range of 350–750 ng/dL used in TRAVERSE may have been too low to detect certain benefits (or harms) of TT.[/B] [B]It is generally recommended to maintain T levels in the mid-normal range (e.g. 550–750 ng/dL), which may be often accomplished with T injections as opposed to T gel. Also, given that TT is often required for long-term (e.g. lifelong) treatment, further study is clearly still needed to determine the long-term safety and efficacy of TT.[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Unveiling the Link: Exploring Testosterone's Impact on Cardiovascular Health
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top